An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13717
Abstract: Eltrombopag, an oral thrombopoietin receptor agonist, is dosed daily to treat chronic immune thrombocytopenia (ITP). As it has a half-life of 26-35 h in ITP patients and requires patents to abide by strict dietary restrictions that… read more here.
Keywords: alternative intermittent; chronic immune; intermittent eltrombopag; treatment ... See more keywords